The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.
West Lafayette-based life sciences contract research firm Bioanalytical Systems Inc. has five directors on its board. If company
founder Pete Kissinger has his way, four of them will soon be replaced.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
Ma quande lingues coalesce, t va semblar un simplificat Angles, quam un skeptic Cambridge amico dit me que Occidental es.
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
It took Pete and Candace Kissinger 33 years to build West Lafayette-based Bioanalytical Systems Inc. into one of the largest
contract research firms in Indiana’s life science sector. It took just a year and a half for them to turn against the company’s new management.
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer’s
disease and muscular dystrophy.
Indiana and Purdue universities are well-positioned to take advantage of the $11.5 billion available for life sciences and
biotech research from the federal stimulus package.
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
The Indiana Innovation Alliance will bring together researchers from both IU and Purdue and keep much intellectual property innovation in Indiana.
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Three entrepreneurs from the medical and software realms are herding angels to invest in upstart life sciences companies in
Indiana.
Lawyers holding doctorates in biotech, biology, chemistry and computer sciences are in high demand by firms with strong intellectual
property practices.
Financially strapped Dow Chemical Co. acknowledges it may sell Indianapolis-based Dow AgroSciences LLC, the ag-chemicals-and-biotech
firm that’s one of the biggest jewels in the city’s life sciences crown.
The Central Indiana Corporate Partnership—the parent of the BioCrossroads, TechPoint and Conexus industry cluster initiatives—let it be known last month that there would be a fourth leg to its economic development stool: clean technology.
NASA begins to award more grants to Indiana firms and universities.
Lilly executives want to make biotech their top focus.
Last fall, BioCrossroads named Leonard J. Betley—chairman of the Richard M. Fairbanks Foundation, the Regenstrief Foundation
and the Walther Cancer Foundation—its inaugural Life Sciences Champion of the Year. IBJ recently caught up with Betley to get his thoughts on the latest life sciences developments and gauge the climate
for fund raising.
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
FAST Diagnostics quickly is becoming one of the more promising companies in Indiana University’s efforts to commercialize its discoveries. Incorporated in November 2006, it is developing a method to measure kidney function faster and more accurately than existing techniques can. While FAST represents speed, the name actually stands for functional assessment and surveillance technology. The fledgling firm so far has attracted more than $4 million from investors, including $2 million from the state’s 21st Century Fund. BioCrossroads, Rose Hulman Ventures…
